Get started
Spruce Biosciences, Inc.Spruce Biosciences, Inc.Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SPRB chart


Full chart

SPRB upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪22.10 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.0519 USD
Net income (FY)
‪−47.92 M‬ USD
Revenue (FY)
‪10.09 M‬ USD
Shares float
‪28.51 M‬
Beta (1Y)
2.02

Employees


Employees (FY)
29
Change (1Y)
+2 +7.41%
Revenue / Employee (1Y)
‪347.90 K‬ USD
Net income / Employee (1Y)
‪−1.65 M‬ USD

About Spruce Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Javier Szwarcberg
Website
sprucebio.com
Headquarters
South San Francisco
Founded
2014
FIGI
BBG00HYZ1522
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

SPRB news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SPRB is 0.5488 USD — it has decreased by −2.41% in the past 24 hours. Watch Spruce Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Spruce Biosciences, Inc. stocks are traded under the ticker SPRB.
SPRB stock has fallen by −9.31% compared to the previous week, the month change is a 21.59% rise, over the last year Spruce Biosciences, Inc. has showed a −50.11% decrease.
We've gathered analysts' opinions on Spruce Biosciences, Inc. future price: according to them, SPRB price has a max estimate of 3.00 USD and a min estimate of 2.00 USD. Watch SPRB chart and read a more detailed Spruce Biosciences, Inc. stock forecast: see what analysts think of Spruce Biosciences, Inc. and suggest that you do with its stocks.
SPRB reached its all-time high on Nov 27, 2020 with the price of 35.6000 USD, and its all-time low was 0.4112 USD and was reached on Aug 12, 2024. View more price dynamics on SPRB chart.
See other stocks reaching their highest and lowest prices.
SPRB stock is 4.99% volatile and has beta coefficient of 2.02. Track Spruce Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Spruce Biosciences, Inc. there?
Today Spruce Biosciences, Inc. has the market capitalization of ‪22.10 M‬, it has decreased by −3.49% over the last week.
Yes, you can track Spruce Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Spruce Biosciences, Inc. is going to release the next earnings report on Nov 20, 2024. Keep track of upcoming events with our Earnings Calendar.
SPRB earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.32 USD resulting in a 31.25% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Spruce Biosciences, Inc. earnings.
Spruce Biosciences, Inc. revenue for the last quarter amounts to ‪1.61 M‬ USD, despite the estimated figure of ‪1.50 M‬ USD. In the next quarter, revenue is expected to reach ‪1.49 M‬ USD.
SPRB net income for the last quarter is ‪−9.18 M‬ USD, while the quarter before that showed ‪−11.63 M‬ USD of net income which accounts for 21.02% change. Track more Spruce Biosciences, Inc. financial stats to get the full picture.
No, SPRB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 29.00 employees. See our rating of the largest employees — is Spruce Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Spruce Biosciences, Inc. EBITDA is ‪−47.43 M‬ USD, and current EBITDA margin is −514.65%. See more stats in Spruce Biosciences, Inc. financial statements.
Like other stocks, SPRB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Spruce Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Spruce Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Spruce Biosciences, Inc. stock shows the sell signal. See more of Spruce Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.